Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
CA 2192079 C · Owner: Viventia Biotech Inc. · Inventors: Dan, Michael D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The variable chains of two human monoclonal antibodies (HMAbs) of the IgM isotype are characterized by elucidation of cDNAs encoding those chains. The HMAbs are specific against cell cycle independent glioma-associated antigen, and the antibodies do not recognize cultured normal human astrocytes. Immunoconjugates based on the sequences identified should target both proliferating and non-proliferating glioma cells in vivo thus providing a , valuable adjunctive therapy in the treatment of these tumors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 16, 1995 and granted January 9, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 16, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 16, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.